Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Exclusion Criteria

• •Diagnosis of a Philadelphia chromosome positive malignancy
• •Acute myeloid leukemia.
• •If the participant is receiving corticosteroids, and the dose has not been stable for ≥7 days.
• •Within the 14 days prior to enrollment, participant has received any antineoplastic therapy (including midostaurin, avapritinib and other tyrosine kinase inhibitors \[TKIs\]) or an investigational agent.
• •Participant has received hydroxyurea within 7 days prior to the first dose of elenestinib (BLU-263).
• •Participant received prior HMA therapy (e.g., azacitidine, decitabine) for the current diagnosis.
• •Participant must not be eligible for allogenic hematopoietic stem cell transplantation.
• •Participant received prior radiotherapy within 14 days of screening BM biopsy.
• •Participant received any hematopoietic growth factor (except erythropoietin) within 14 days of screening BM biopsy, or requiring growth factors to maintain adequate neutrophil or platelet levels.
• •Those participants maintained on a chronic dose of erythropoietin, whose hemoglobin is stable, and dose of erythropoietin has not been changed in the prior 28 days are allowed on study.
• •Participant received \>1 prior selective KIT inhibitor (eg: avapritinib or bezuclastinib).
• •Participant have any of the following laboratory abnormalities on last laboratory assessment within 14 days prior to the first dose of initiation of study drug: a. Alanine aminotransferase and aspartate aminotransferase \> 3 × ULN; \> 5 × ULN if associated with clinically suspected liver infiltration by mastocytosis or another disease for which the patient enrolled into the study b. Total bilirubin \> 1.5 × ULN; \> 3 × ULN if associated with liver infiltration by the disease being treated or in the presence of Gilbert's Disease. (In the case of Gilbert's disease, a direct bilirubin \> 2.0 ULN would be an exclusion) c. Estimated (Cockcroft-Gault formula) or measured creatinine clearance \< 40 mL/min d. Absolute neutrophil count \< 0.5 × 10\^9/L
• •Participant has had a major surgical procedure within 14 days of the first dose of study drug.
• •History of another primary malignancy that has been diagnosed or required therapy within 1 year prior to the first dose of study drug. The following are exempt from the 1-year limit: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, GI stromal tumor, and completely resected carcinoma in situ of any site.
• •Mean resting QTcF \> 480 msec, a history of prolonged QT syndrome or Torsades de pointes, or a familial history of prolonged QT syndrome.
• •Clinically significant, uncontrolled, cardiovascular disease.
• •Arm 1 (Monotherapy):
• •Myelodysplastic Syndrome (MDS) that is very high- or high-risk as defined by the International Prognostic Scoring System for Myelodysplastic Syndromes-Revised (IPSS-R).
• •A myeloid AHN with ≥10% BM or peripheral blood blasts.
• •Platelet count \<50 x 10\^9/L (within 4 weeks prior to the first dose of study drug) or receiving platelet transfusions or thrombopoietin receptor agonists (TPO-RA) within the prior 14 days.